Securities code: 301122 securities abbreviation: adoptive shares Announcement No.: 2022-009 adoptive Technology Co., Ltd
On the adoption of medical technology in Jiangsu, a wholly-owned subsidiary
Announcement on capital increase of Technology Co., Ltd
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Adoptive Technology Co., Ltd. (hereinafter referred to as “the company” or “adoptive shares”) held the seventh meeting of the second board of directors on February 16, 2022, deliberated and adopted the proposal on capital increase of Jiangsu adoptive Medical Technology Co., Ltd., a wholly-owned subsidiary. The details are hereby announced as follows:
1、 Overview of this capital increase
Jiangsu adoptive Medical Technology Co., Ltd. (hereinafter referred to as “adoptive medical”) is a wholly-owned subsidiary of the company. In order to promote the implementation of the plan for the use of raised funds, the company plans to use the raised funds of 153892700.00 yuan and its own funds of 1107300.00 yuan to adopt medical capital increase for the wholly-owned subsidiary, and all of them will enter the registered capital, It is mainly used for the “construction project of medical injection and puncture instrument industrial park with an annual output of 920 million pieces (sets)” and “construction project of R & D center”. After the capital increase is completed, the registered capital of medical treatment will be increased from 130 million yuan to 285 million yuan.
This capital increase does not constitute a connected transaction, nor does it constitute a major asset reorganization as stipulated in the administrative measures for major asset reorganization of listed companies.
2、 Basic information of the subject matter of this capital increase
Company name: Jiangsu adoptive Medical Technology Co., Ltd
Unified social credit Code: 913202810710262756
Legal representative: Army
Date of establishment: June 8, 2013
Registered capital: RMB 13 million
Registered address: No. 23, Huanxi Road, Zhutang Town, Jiangyin City
Business scope: licensed items: production of sanitary products and disposable medical products; Disinfectant production (excluding hazardous chemicals); Road cargo transportation (excluding dangerous goods); Import and export of goods; Technology import and export; Import and export agency; Production of class II medical devices; Production of class III medical devices; Category III medical device business (items that must be approved according to law can only be carried out after being approved by relevant departments, and the specific business items shall be subject to the approval results) general items: technical services, technology development, technical consultation, technical exchange, technology transfer and technology promotion; Production of class I medical devices; Sales of class I medical devices; Sales of class II medical devices; Sales of sanitary supplies and disposable medical supplies; Production of labor protection articles; Sales of labor protection articles; Production of special labor protection articles; Sales of special labor protection articles; Sales of disinfectants (excluding hazardous chemicals); Wholesale of hardware products; Retail of hardware products; Sales of plastic products; Non residential real estate leasing; Leasing of machinery and equipment (except for projects subject to approval according to law, carry out business activities independently according to law with business license)
Main financial data: as of September 30, 2021, the total assets of medical treatment adopted were 302.0382 million yuan and the net assets were 248.9868 million yuan. From January to September 2021, the operating income was 159.7467 million yuan and the net profit was 35.8507 million yuan. (the above data has not been audited)
Shareholders: the company holds 100% equity
3、 Impact of this capital increase on the company
1. The main source of this capital increase is the funds raised by the company’s initial public offering. The use and purpose of the raised funds are in line with the development direction of the company’s main business, which is conducive to meeting the capital needs of the raised investment projects and ensuring the smooth implementation of the raised investment projects.
2. This capital increase does not change the investment direction and project construction content of the raised funds, and will not have a substantive impact on the implementation of the raised investment projects. It meets the business needs of the company and does not damage the interests of the company and shareholders.
3. After the completion of this capital increase, the company’s shareholding ratio in the adoption of medical treatment is still 100%, which will not change the scope of the company’s consolidated statements and have an adverse impact on the company’s financial and operating conditions.
4、 Documents for future reference
1. Adopting the resolution of the seventh meeting of the second board of directors of science and Technology Co., Ltd
It is hereby announced.
Board of directors of adoptive Technology Co., Ltd. February 16, 2022
